High-performance liquid chromatography and thin-layer chromatography for the simultaneous quantitation of rabeprazole and mosapride in pharmaceutical products.

Simple, sensitive high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC) methods are developed for the quantitative estimation of rabeprazole and mosapride in their combined pharmaceutical dosage forms. In HPLC, rabeprazole and mosapride are chromatographed using 0.01M 6.5 pH ammonium acetate buffer-methanol-acetonitrile (40:20:40, v/v, pH 5.70+/-0.02) as the mobile phase at a flow rate of 1.0 mL/min. In TLC, the mobile phase is ethyl acetate-methanol-benzene (2:0.5:2.5, v/v). Both the drugs are scanned at 276 nm. The retention times of rabeprazole and mosapride are found to be 4.93+/-0.01 and 9.79+/-0.02, respectively. The Rf values of rabeprazole and mosapride are found to be 0.42+/-0.02 and 0.61+/-0.02, respectively. The linearities of rabeprazole and mosapride are in the range of 400-2000 ng/mL and 300-1500 ng/mL, respectively, for HPLC; in TLC, the linearities of rabeprazole and mosapride are in the range of 400-1200 ng/spot and 300-900 ng/spot, respectively. The limit of detection is found to be 97.7 ng/mL for rabeprazole and 97.6 ng/mL for mosapride in HPLC; in TLC the limit of detection is found to be 132.29 ng/spot for rabeprazole and 98.25 ng/spot for mosapride. The proposed methods can be applied to the determination of rabeprazole and mosapride in combined pharmaceutical products.

[1]  P. Mahulikar,et al.  Estimation of Rabeprazole Sodium in tablet dosage form by rapid isocratic reversed phase high performance liquid chromatography using volatile buffer additives , 2006 .

[2]  N. Yasui-Furukori,et al.  Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  N. V. Ramakrishna,et al.  Validation and application of a high-performance liquid chromatography--tandem mass spectrometry assay for mosapride in human plasma. , 2005, Biomedical chromatography : BMC.

[4]  L. Rui,et al.  Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma. , 2005, Rapid communications in mass spectrometry : RCM.

[5]  N. V. Ramakrishna,et al.  High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  A. El-Gindy,et al.  Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products. , 2003, Journal of pharmaceutical and biomedical analysis.

[7]  T. K. Murthy,et al.  A validated RP-HPLC method for the determination of mosapride citrate in bulk drug samples and pharmaceutical formulations. , 2002, Die Pharmazie.

[8]  T. K. Murthy,et al.  The Determination of Mosapride Citrate in Bulk Drug Samples and Pharmaceutical Dosage Forms Using HPLC , 2002, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[9]  M. Kayano,et al.  Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. , 1994, Journal of chromatography. B, Biomedical applications.

[10]  J. W. COOK,et al.  “The Merck Index” , 1953, Nature.